HomeCompareGRPH vs KO

GRPH vs KO: Dividend Comparison 2026

GRPH yields 64.78% · KO yields 2.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRPH wins by $787.3K in total portfolio value
10 years
GRPH
GRPH
● Live price
64.78%
Share price
$3.18
Annual div
$2.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$821.3K
Annual income
$203,467.89
Full GRPH calculator →
KO
The Coca-Cola Company
● Live price
2.70%
Share price
$76.27
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,303.79
Full KO calculator →

Portfolio growth — GRPH vs KO

📍 GRPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRPHKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRPH + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRPH pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRPH
Annual income on $10K today (after 15% tax)
$5,506.29/yr
After 10yr DRIP, annual income (after tax)
$172,947.71/yr
KO
Annual income on $10K today (after 15% tax)
$229.58/yr
After 10yr DRIP, annual income (after tax)
$3,658.22/yr
At 15% tax rate, GRPH beats the other by $169,289.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRPH + KO for your $10,000?

GRPH: 50%KO: 50%
100% KO50/50100% GRPH
Portfolio after 10yr
$427.7K
Annual income
$103,885.84/yr
Blended yield
24.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

GRPH
Analyst Ratings
7
Hold
1
Sell
Consensus: Hold
Price Target
$4.00
+25.8% upside vs current
Range: $2.00 — $7.00
Altman Z
5.3
Piotroski
4/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.3% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRPH buys
0
KO buys
0
No recent congressional trades found for GRPH or KO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRPHKO
Forward yield64.78%2.70%
Annual dividend / share$2.06$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%24.3%
Portfolio after 10y$821.3K$34.1K
Annual income after 10y$203,467.89$4,303.79
Total dividends collected$690.7K$15.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$4.00$84.88

Year-by-year: GRPH vs KO ($10,000, DRIP)

YearGRPH PortfolioGRPH Income/yrKO PortfolioKO Income/yrGap
1← crossover$17,178$6,477.99$10,846$335.73+$6.3KGRPH
2$28,780$10,399.89$11,829$430.64+$17.0KGRPH
3$47,079$16,284.27$12,988$555.50+$34.1KGRPH
4$75,270$24,895.34$14,372$721.34+$60.9KGRPH
5$117,738$37,198.68$16,049$944.01+$101.7KGRPH
6$180,359$54,379.70$18,114$1,246.74+$162.2KGRPH
7$270,837$77,853.00$20,702$1,664.24+$250.1KGRPH
8$399,056$109,260.19$24,008$2,249.48+$375.0KGRPH
9$577,444$150,453.99$28,317$3,085.19+$549.1KGRPH
10$821,333$203,467.89$34,065$4,303.79+$787.3KGRPH

GRPH vs KO: Complete Analysis 2026

GRPHStock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full GRPH Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this GRPH vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRPH vs SCHDGRPH vs JEPIGRPH vs OGRPH vs MAINGRPH vs PEPGRPH vs PGGRPH vs JNJGRPH vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.